Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001946641 | SCV002235128 | pathogenic | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg682Glufs*23) in the ALPK3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALPK3 are known to be pathogenic (PMID: 21441111, 26846950, 27106955, 34263907). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ALPK3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1455524). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002423140 | SCV002719821 | likely pathogenic | Cardiovascular phenotype | 2021-06-24 | criteria provided, single submitter | clinical testing | The c.2044delA variant, located in coding exon 5 of the ALPK3 gene, results from a deletion of one nucleotide at nucleotide position 2044, causing a translational frameshift with a predicted alternate stop codon (p.R682Efs*23). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |